NetScientific business unit eyes opportunities to significantly boost top revenues
Chairman John Clarkson said: “In what has been a challenging year for ProAxsis, positive management actions have helped transform the company’s outlook"
Company
EMV Capital
LON:NSCI
EMV Capital plc is a deep tech and life sciences venture capital investment group with an international portfolio of high-growth companies. With a strategic focus on generating superior returns for investors from the fast-growing sectors and technologies that will define our future, the group invests in, manages, and strengthens early stage IP-rich companies.
424 stories · page 8 of 22
NetScientific hails the potential of investee company's cancer immunotherapy
The latest data points to a 71% response rate to the drug
NetScientific’s EMV Capital assists PointGrab funding for social distancing technology
"We worked with the management team throughout the COVID crisis to help evolve corporate and investment strategy in response to the once-in-a-generation shifts in corporate practices unleashed by COVID,” said NetScientific chief executive D
NetScientific portfolio firm PDS Biotech sells off New Jersey tax benefits
The company said PDS has received US$4.5mln from the sale of the benefits, which fall under the New Jersey Technology Business Tax Certificate Transfer Net Operating Loss program
Netscientific’s ProAxsis awarded UK grant to fund COVID-19 testing technology
The company said the Innovate UK grant will co-fund a £390,000 project to develop novel protease biomarkers to identify high-risk COVID-19 patients
NetScientific investee company receives second funding tranche from Chinese pharma giant
Glycotest Inc has received US$3mln, which help fund the commercialisation of its liver cancer diagnostic
Shares in NetScientific up strongly after portfolio company's drug is given Merck boost
NetScientific invested £1.76mln for a 14.85% shareholding in PDS Biotechnology
NetScientific backs PDS Biotechnology's focus on combination immuno-oncology therapies
Portfolio company PDS intends to “continue to advance our previously announced combination studies with PDS0101 in various advanced HPV-associated cancers”
NetScientific surges as portfolio firm PDS unveils positive data from HPV treatment
PDS said 60% of patients in a Phase 1 trial had responded to PDS0101, which is aiming to treat high-risk, cancer-causing types of HPV
NetScientific PLC portfolio company PDS Biotech agrees deal to raise up to US$20mln
The agreement will see the PDS direct Aspire Capital to buy up to 100,000 shares per day whenever the stock price exceeds 50 US cents
Archive
Proactive news snapshot: NetScientific , Metal Tiger, ANGLE …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
ANGLE points upwards after successful breast cancer trial outcome
A look at the day's major movers, including Karelian, UniVision, Cambria Africa, Bagir, Nautilus Marine, Stride Gaming and Patagonia Gold
NetScientific rockets as ProAxsis sees positive early trial data for NEATstik lung disease test
The data, published in the peer-reviewed European Respiratory Journal, found that NEATstik was able to replicate the results of existing tests for chest infections within only ten minutes
Investments and investor services
FTSE 100 closes down after latest Trump trade war stunt
The Dow Jones suffered a 300 point fall in the first half hour of trading
NetScientific ‘confident’ in prospects of its three portfolio companies
Here we take a closer look at healthcare investor NetScientific PLC (LON:NSCI)
Archive
Informa strikes TMT swap deal with IHS Markit
A look at some of the top risers and fallers on the London Stock Exchange on Wednesday, including 21st Century Technology, Thruvision, Hargreaves Services, Management Resource Solutions, SafeCharge International, IG Group, Pets at Home, and
Archive
Proactive news snapshot: Sound Energy, Bushveld Minerals, Motif Bio, IXICO …
A glance at some of the day's highlights from the Proactive Investors newswire
NetScientific to focus on extending lifespan as CEO reiterates confidence in portfolio firms
CEO Ian Postlethwaite said the healthcare commercialisation firm had taken measures to reduce its central function costs and was expected to have sufficient cash to operate until the end of 2020
Archive
FTSE 100 closes slightly ahead but Wall Street shares slide
The Footsie closed out at 7,334 - up around five points, while mid-cap index was firmly lower- down 129 points at 19,307
Netscientific surges as peer-reviewed article confirms potential of PDS Biotech’s Versamune immunotherapy platform
In the article, researchers described how the Versamune platform recruits and activates killer T-cells to recognise and effectively attack cancer cells while simultaneously making cancer cells more susceptible to T-cell attack